SG11201408028YA - METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES - Google Patents
METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVESInfo
- Publication number
- SG11201408028YA SG11201408028YA SG11201408028YA SG11201408028YA SG11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA SG 11201408028Y A SG11201408028Y A SG 11201408028YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- serine protease
- california
- applicant
- rule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188587 A1 (51) International Patent Classification: C07K1/22 (2006.01) C12N 9/64 (2006.01) (21) International Application Number: PCT/US2013/045496 (22) International Filing Date: 12 June 2013 (12.06.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/659,821 14 June 2012 (14.06.2012) US (71) Applicant: PORTOLA PHARMACEUTICALS, INC. [US/US]; 270 E. Grand Avenue, South San Francisco, California 94080 (US). (72) Inventors: LU, Genmin; 1439 El Camino Real, Apt 9, Burlingame, California 94010 (US). SINHA, Uma; 808 Junipero Serra Blvd., San Francisco, California 94127 (US). (74) Agents: TANNER, Lorna L. et al.; Foley & Lardner LLP, 3000 K Street N.W., Suite 600, Washington, DC 20007- 5109 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) (54) Title: METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES l> 00 00 00 T-H rn T-H o CJ o - A280 ELISA CM < 0 0- O O -O- O- O O < /: \ t \ // \ -*-V / \ / \ —£ - O O—O 0 0 0 0 A 0 80000 60000 - E 40000 < to 20000 4 6 Fraction # 10 12 r-Antidote MK r-Antidote (57) Abstract: Disclosed herein are methods and kits for purifying a serine protease. The methods entail loading the serine protease to a soybean trypsin inhibitor (STI) based affinity chromatograph, and eluting the serine protease with an elution buffer comprising an agent that disrupts interaction between the STI and the serine protease
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261659821P | 2012-06-14 | 2012-06-14 | |
PCT/US2013/045496 WO2013188587A1 (en) | 2012-06-14 | 2013-06-12 | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408028YA true SG11201408028YA (en) | 2015-01-29 |
Family
ID=48700721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408028YA SG11201408028YA (en) | 2012-06-14 | 2013-06-12 | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
Country Status (14)
Country | Link |
---|---|
US (1) | US20150239929A1 (en) |
EP (1) | EP2861614B1 (en) |
JP (1) | JP6261093B2 (en) |
KR (2) | KR102100629B1 (en) |
CN (1) | CN104379594B (en) |
AU (1) | AU2013274288B2 (en) |
CA (1) | CA2876361C (en) |
ES (1) | ES2612458T3 (en) |
HK (1) | HK1209760A1 (en) |
IL (1) | IL235896B (en) |
PT (1) | PT2861614T (en) |
SG (1) | SG11201408028YA (en) |
WO (1) | WO2013188587A1 (en) |
ZA (1) | ZA201408921B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
BE1022313B1 (en) | 2014-11-28 | 2016-03-15 | Puratos N.V. | ENZYM INHIBITOR COMPLEXES |
DK3472314T3 (en) * | 2016-06-17 | 2021-07-26 | Alexion Pharma Inc | PREPARATION OF FACTOR XA DERIVATIVES |
US20180037604A1 (en) * | 2016-08-04 | 2018-02-08 | Stelis Biopharma Private Limited | Process for the purification of recombinant proteins |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8528321D0 (en) * | 1985-11-18 | 1985-12-24 | Ciba Geigy Ag | Modified fibrinolytic agents |
KR960016514B1 (en) * | 1990-10-12 | 1996-12-14 | 쿨리건 인터내셔널 컴패니 | Faucet-mounted microbial filter |
CN1297896A (en) * | 1999-11-29 | 2001-06-06 | 中国科学技术大学 | Method of extracting activated prothrombin X(FXa) effectively |
EP2915564B1 (en) * | 2007-09-28 | 2020-11-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor XA inhibitors and methods of using the same |
CA2742817A1 (en) * | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
EP3604510A1 (en) * | 2009-03-30 | 2020-02-05 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
WO2010127980A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Fret-based binding assay |
-
2013
- 2013-06-12 KR KR1020147036450A patent/KR102100629B1/en active IP Right Grant
- 2013-06-12 KR KR1020207010091A patent/KR102210574B1/en active IP Right Grant
- 2013-06-12 ES ES13732317.6T patent/ES2612458T3/en active Active
- 2013-06-12 CA CA2876361A patent/CA2876361C/en active Active
- 2013-06-12 EP EP13732317.6A patent/EP2861614B1/en active Active
- 2013-06-12 JP JP2015517406A patent/JP6261093B2/en active Active
- 2013-06-12 WO PCT/US2013/045496 patent/WO2013188587A1/en active Application Filing
- 2013-06-12 SG SG11201408028YA patent/SG11201408028YA/en unknown
- 2013-06-12 US US14/406,645 patent/US20150239929A1/en not_active Abandoned
- 2013-06-12 AU AU2013274288A patent/AU2013274288B2/en active Active
- 2013-06-12 PT PT137323176T patent/PT2861614T/en unknown
- 2013-06-12 CN CN201380033420.3A patent/CN104379594B/en active Active
-
2014
- 2014-11-25 IL IL235896A patent/IL235896B/en active IP Right Grant
- 2014-12-04 ZA ZA2014/08921A patent/ZA201408921B/en unknown
-
2015
- 2015-10-20 HK HK15110322.1A patent/HK1209760A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2861614B1 (en) | 2016-11-30 |
AU2013274288B2 (en) | 2017-08-17 |
CN104379594A (en) | 2015-02-25 |
JP2015521471A (en) | 2015-07-30 |
CN104379594B (en) | 2017-06-23 |
WO2013188587A1 (en) | 2013-12-19 |
CA2876361A1 (en) | 2013-12-19 |
EP2861614A1 (en) | 2015-04-22 |
AU2013274288A1 (en) | 2015-01-15 |
US20150239929A1 (en) | 2015-08-27 |
KR102210574B1 (en) | 2021-02-01 |
ES2612458T3 (en) | 2017-05-17 |
PT2861614T (en) | 2017-01-26 |
ZA201408921B (en) | 2020-08-26 |
IL235896B (en) | 2019-02-28 |
KR102100629B1 (en) | 2020-04-16 |
KR20150027765A (en) | 2015-03-12 |
JP6261093B2 (en) | 2018-01-17 |
CA2876361C (en) | 2020-06-30 |
HK1209760A1 (en) | 2016-04-08 |
IL235896A0 (en) | 2015-01-29 |
KR20200039828A (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201408261UA (en) | Syringe | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201408028YA (en) | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201407674TA (en) | D-amino acid compounds for liver disease | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG11201406625XA (en) | Anti-fcrn antibodies | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201408174UA (en) | Antibody formulation | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |